David Williams
Concepts (535)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Enzyme Inhibitors | 6 | 2023 | 386 | 0.890 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2023 | 16 | 0.670 |
Why?
| Hypophosphatasia | 1 | 2018 | 8 | 0.650 |
Why?
| Genetic Engineering | 1 | 2018 | 24 | 0.640 |
Why?
| Alkaline Phosphatase | 1 | 2018 | 95 | 0.620 |
Why?
| Disease Models, Animal | 5 | 2019 | 1458 | 0.620 |
Why?
| Phenylenediamines | 1 | 2018 | 5 | 0.620 |
Why?
| Cerebrovascular Circulation | 3 | 2016 | 132 | 0.570 |
Why?
| Proto-Oncogene Proteins c-met | 5 | 2010 | 21 | 0.550 |
Why?
| Retroviridae Infections | 2 | 2013 | 2 | 0.550 |
Why?
| Personnel, Hospital | 2 | 2006 | 20 | 0.530 |
Why?
| Tinnitus | 2 | 2017 | 60 | 0.530 |
Why?
| Transcranial Magnetic Stimulation | 2 | 2017 | 70 | 0.520 |
Why?
| Aminopyridines | 3 | 2010 | 15 | 0.510 |
Why?
| Suction | 2 | 2013 | 24 | 0.480 |
Why?
| Female | 49 | 2024 | 26635 | 0.470 |
Why?
| Amines | 2 | 2014 | 41 | 0.460 |
Why?
| Methamphetamine | 5 | 2014 | 200 | 0.450 |
Why?
| Macaca mulatta | 2 | 2013 | 93 | 0.450 |
Why?
| Humans | 62 | 2024 | 50208 | 0.440 |
Why?
| Xenotropic murine leukemia virus-related virus | 1 | 2012 | 1 | 0.430 |
Why?
| Wounds and Injuries | 2 | 2006 | 281 | 0.420 |
Why?
| Antibodies, Monoclonal | 5 | 2014 | 460 | 0.410 |
Why?
| Male | 44 | 2024 | 25399 | 0.410 |
Why?
| Heart Rate | 5 | 2019 | 298 | 0.400 |
Why?
| Rural Health Services | 2 | 2013 | 164 | 0.400 |
Why?
| Structure-Activity Relationship | 11 | 2023 | 401 | 0.400 |
Why?
| Caregivers | 3 | 2019 | 212 | 0.390 |
Why?
| Protein Kinase Inhibitors | 3 | 2010 | 206 | 0.390 |
Why?
| Intermittent Positive-Pressure Ventilation | 1 | 2011 | 19 | 0.370 |
Why?
| Infant, Very Low Birth Weight | 1 | 2011 | 47 | 0.370 |
Why?
| Obesity | 6 | 2024 | 1108 | 0.370 |
Why?
| Cost-Benefit Analysis | 2 | 2015 | 273 | 0.360 |
Why?
| Depressive Disorder | 2 | 2010 | 339 | 0.360 |
Why?
| United States Department of Veterans Affairs | 3 | 2021 | 288 | 0.360 |
Why?
| Telemedicine | 3 | 2013 | 449 | 0.350 |
Why?
| Animals | 30 | 2021 | 13246 | 0.350 |
Why?
| Antineoplastic Agents | 5 | 2010 | 1186 | 0.350 |
Why?
| Intubation, Intratracheal | 1 | 2011 | 118 | 0.340 |
Why?
| Respiration, Artificial | 2 | 2016 | 274 | 0.340 |
Why?
| Breast Feeding | 2 | 2022 | 188 | 0.330 |
Why?
| Maternal Nutritional Physiological Phenomena | 2 | 2020 | 57 | 0.330 |
Why?
| Dietary Supplements | 3 | 2018 | 434 | 0.320 |
Why?
| Time Factors | 10 | 2020 | 2922 | 0.310 |
Why?
| Insulin Resistance | 2 | 2020 | 262 | 0.300 |
Why?
| Blood Pressure | 4 | 2016 | 524 | 0.300 |
Why?
| Gait Disorders, Neurologic | 2 | 2018 | 36 | 0.300 |
Why?
| Leptin | 2 | 2022 | 140 | 0.290 |
Why?
| Dietary Proteins | 2 | 2020 | 239 | 0.280 |
Why?
| Infant, Newborn | 9 | 2021 | 2766 | 0.280 |
Why?
| Brain | 5 | 2021 | 1328 | 0.270 |
Why?
| Parkinson Disease | 2 | 2018 | 151 | 0.270 |
Why?
| Accidents, Occupational | 1 | 2006 | 19 | 0.270 |
Why?
| Infant, Premature | 5 | 2016 | 319 | 0.250 |
Why?
| Adiposity | 2 | 2024 | 133 | 0.250 |
Why?
| Cerebral Hemorrhage | 2 | 2016 | 104 | 0.250 |
Why?
| Occupational Diseases | 1 | 2006 | 88 | 0.250 |
Why?
| Rats, Sprague-Dawley | 13 | 2014 | 1586 | 0.240 |
Why?
| Cross-Over Studies | 7 | 2017 | 218 | 0.230 |
Why?
| Pregnancy | 11 | 2024 | 2604 | 0.230 |
Why?
| Veterans | 2 | 2021 | 560 | 0.230 |
Why?
| Depression | 3 | 2014 | 570 | 0.230 |
Why?
| Infant, Premature, Diseases | 2 | 2016 | 94 | 0.230 |
Why?
| Insulin | 3 | 2022 | 456 | 0.220 |
Why?
| Ethers | 1 | 2023 | 8 | 0.220 |
Why?
| Internship and Residency | 2 | 2019 | 441 | 0.220 |
Why?
| Pyrroles | 3 | 2008 | 69 | 0.220 |
Why?
| Executive Function | 2 | 2021 | 77 | 0.220 |
Why?
| Stress Disorders, Post-Traumatic | 2 | 2019 | 365 | 0.210 |
Why?
| Sertraline | 2 | 2014 | 46 | 0.210 |
Why?
| Adult | 17 | 2019 | 13324 | 0.200 |
Why?
| Students, Medical | 2 | 2017 | 155 | 0.200 |
Why?
| Maternal-Fetal Exchange | 2 | 2020 | 43 | 0.200 |
Why?
| Pedunculopontine Tegmental Nucleus | 2 | 2012 | 24 | 0.200 |
Why?
| Liver Failure, Acute | 1 | 2022 | 54 | 0.200 |
Why?
| Microsomes, Liver | 4 | 2018 | 186 | 0.200 |
Why?
| HeLa Cells | 2 | 2023 | 260 | 0.200 |
Why?
| End Stage Liver Disease | 1 | 2022 | 45 | 0.190 |
Why?
| Energy Metabolism | 2 | 2021 | 279 | 0.190 |
Why?
| Body Composition | 2 | 2020 | 319 | 0.190 |
Why?
| Middle Aged | 12 | 2019 | 12206 | 0.190 |
Why?
| Mice | 14 | 2021 | 5759 | 0.190 |
Why?
| Phencyclidine | 2 | 2011 | 38 | 0.190 |
Why?
| Myocardium | 2 | 2021 | 438 | 0.190 |
Why?
| Rats | 13 | 2014 | 3299 | 0.190 |
Why?
| Olivary Nucleus | 2 | 2011 | 7 | 0.190 |
Why?
| Myoglobin | 1 | 2021 | 25 | 0.190 |
Why?
| Purkinje Cells | 2 | 2011 | 17 | 0.190 |
Why?
| Evoked Potentials | 1 | 2021 | 72 | 0.190 |
Why?
| Cocaine-Related Disorders | 2 | 2014 | 205 | 0.180 |
Why?
| Infant Food | 1 | 2020 | 28 | 0.180 |
Why?
| Growth | 1 | 2020 | 40 | 0.180 |
Why?
| Spumavirus | 1 | 2020 | 1 | 0.180 |
Why?
| Bottle Feeding | 1 | 2020 | 34 | 0.180 |
Why?
| Body Temperature Regulation | 1 | 2020 | 24 | 0.180 |
Why?
| Crystallography, X-Ray | 6 | 2010 | 148 | 0.180 |
Why?
| Blood Glucose | 2 | 2020 | 435 | 0.180 |
Why?
| Acetaminophen | 2 | 2022 | 283 | 0.180 |
Why?
| Neurons | 3 | 2012 | 460 | 0.180 |
Why?
| Brain Concussion | 1 | 2021 | 109 | 0.170 |
Why?
| Concept Formation | 1 | 2019 | 12 | 0.170 |
Why?
| Temperature | 1 | 2020 | 168 | 0.170 |
Why?
| Genome, Viral | 1 | 2020 | 79 | 0.170 |
Why?
| Phenotype | 2 | 2021 | 733 | 0.170 |
Why?
| Energy Intake | 1 | 2020 | 165 | 0.170 |
Why?
| Hepatic Veno-Occlusive Disease | 1 | 2019 | 10 | 0.170 |
Why?
| Eating | 1 | 2020 | 161 | 0.170 |
Why?
| Case-Control Studies | 4 | 2019 | 1126 | 0.170 |
Why?
| Patient Care Team | 3 | 2013 | 257 | 0.170 |
Why?
| Diastole | 2 | 2016 | 71 | 0.160 |
Why?
| Athletic Injuries | 1 | 2021 | 190 | 0.160 |
Why?
| Middle Cerebral Artery | 2 | 2016 | 35 | 0.160 |
Why?
| Diabetes, Gestational | 1 | 2019 | 52 | 0.160 |
Why?
| Freezing Reaction, Cataleptic | 1 | 2018 | 5 | 0.160 |
Why?
| Virus Replication | 1 | 2020 | 140 | 0.160 |
Why?
| Feedback | 1 | 2019 | 52 | 0.160 |
Why?
| Sheep | 1 | 2018 | 90 | 0.160 |
Why?
| Point Mutation | 1 | 2018 | 65 | 0.160 |
Why?
| Colorectal Surgery | 1 | 2018 | 17 | 0.160 |
Why?
| Pyridones | 2 | 2009 | 34 | 0.160 |
Why?
| Cannabidiol | 1 | 2019 | 38 | 0.160 |
Why?
| Receptors, Growth Factor | 2 | 2008 | 7 | 0.160 |
Why?
| Body Mass Index | 4 | 2024 | 656 | 0.160 |
Why?
| Treatment Outcome | 7 | 2017 | 5155 | 0.160 |
Why?
| Arkansas | 6 | 2019 | 1985 | 0.160 |
Why?
| Mental Health Services | 1 | 2021 | 199 | 0.160 |
Why?
| Burnout, Professional | 1 | 2019 | 51 | 0.160 |
Why?
| Child | 8 | 2024 | 6851 | 0.160 |
Why?
| Cell Line, Tumor | 7 | 2017 | 1416 | 0.160 |
Why?
| Military Personnel | 2 | 2019 | 161 | 0.160 |
Why?
| Certification | 1 | 2018 | 49 | 0.160 |
Why?
| Bone Development | 1 | 2018 | 64 | 0.160 |
Why?
| Blood Flow Velocity | 3 | 2016 | 101 | 0.150 |
Why?
| Foot | 1 | 2018 | 42 | 0.150 |
Why?
| Ethanol | 2 | 2011 | 341 | 0.150 |
Why?
| Walking | 1 | 2018 | 96 | 0.150 |
Why?
| United States | 7 | 2021 | 4874 | 0.150 |
Why?
| Action Potentials | 3 | 2012 | 132 | 0.150 |
Why?
| Cognition | 1 | 2020 | 335 | 0.150 |
Why?
| Proto-Oncogene Proteins | 2 | 2008 | 149 | 0.150 |
Why?
| Psychiatry | 2 | 2017 | 105 | 0.150 |
Why?
| Risk Factors | 6 | 2019 | 3629 | 0.140 |
Why?
| Parathyroid Hormone-Related Protein | 1 | 2017 | 23 | 0.140 |
Why?
| Cellular Microenvironment | 1 | 2017 | 26 | 0.140 |
Why?
| Electroacupuncture | 1 | 2016 | 2 | 0.140 |
Why?
| Platelet Activation | 1 | 2017 | 47 | 0.140 |
Why?
| Pilot Projects | 3 | 2017 | 697 | 0.140 |
Why?
| Epinephrine | 1 | 2017 | 96 | 0.140 |
Why?
| Blood Specimen Collection | 1 | 2016 | 34 | 0.140 |
Why?
| Combat Disorders | 1 | 2016 | 37 | 0.140 |
Why?
| Substance-Related Disorders | 2 | 2014 | 601 | 0.140 |
Why?
| Perception | 1 | 2017 | 116 | 0.140 |
Why?
| Attention | 1 | 2017 | 175 | 0.140 |
Why?
| Citrus paradisi | 2 | 2008 | 10 | 0.140 |
Why?
| Food-Drug Interactions | 2 | 2008 | 14 | 0.140 |
Why?
| Temporal Lobe | 2 | 2017 | 70 | 0.130 |
Why?
| Pain | 2 | 2016 | 381 | 0.130 |
Why?
| Neonatal Screening | 1 | 2016 | 47 | 0.130 |
Why?
| Career Choice | 1 | 2017 | 111 | 0.130 |
Why?
| Quinolines | 2 | 2007 | 41 | 0.130 |
Why?
| Itraconazole | 2 | 2008 | 40 | 0.130 |
Why?
| Cell Membrane | 1 | 2017 | 251 | 0.130 |
Why?
| Serotonin | 1 | 2017 | 153 | 0.130 |
Why?
| Cerebral Ventricles | 1 | 2016 | 28 | 0.130 |
Why?
| Antibodies, Viral | 2 | 2013 | 88 | 0.130 |
Why?
| Melatonin | 1 | 2015 | 16 | 0.130 |
Why?
| Arterial Pressure | 1 | 2016 | 43 | 0.130 |
Why?
| Quality of Life | 2 | 2019 | 839 | 0.130 |
Why?
| Physicians | 1 | 2019 | 230 | 0.130 |
Why?
| Muscle, Skeletal | 1 | 2021 | 765 | 0.130 |
Why?
| Bone Neoplasms | 1 | 2017 | 183 | 0.120 |
Why?
| Cholinergic Agonists | 2 | 2011 | 10 | 0.120 |
Why?
| Xenograft Model Antitumor Assays | 3 | 2010 | 212 | 0.120 |
Why?
| Quality-Adjusted Life Years | 2 | 2015 | 63 | 0.120 |
Why?
| Blood Platelets | 1 | 2017 | 249 | 0.120 |
Why?
| Signal Transduction | 2 | 2022 | 1622 | 0.120 |
Why?
| Excitatory Amino Acid Agonists | 2 | 2011 | 20 | 0.120 |
Why?
| Amphetamine | 1 | 2014 | 38 | 0.120 |
Why?
| Cell Differentiation | 1 | 2017 | 650 | 0.120 |
Why?
| Severity of Illness Index | 4 | 2022 | 951 | 0.120 |
Why?
| Cyclohexanecarboxylic Acids | 1 | 2014 | 18 | 0.120 |
Why?
| Autistic Disorder | 1 | 2015 | 120 | 0.120 |
Why?
| Massage | 1 | 2014 | 6 | 0.120 |
Why?
| Drinking | 2 | 2020 | 38 | 0.120 |
Why?
| Osteoclasts | 1 | 2017 | 428 | 0.110 |
Why?
| Behavior Therapy | 1 | 2015 | 181 | 0.110 |
Why?
| Equipment Failure Analysis | 1 | 2013 | 46 | 0.110 |
Why?
| gamma-Aminobutyric Acid | 1 | 2014 | 65 | 0.110 |
Why?
| Simian foamy virus | 1 | 2013 | 1 | 0.110 |
Why?
| Simian Acquired Immunodeficiency Syndrome | 1 | 2013 | 3 | 0.110 |
Why?
| Aged | 6 | 2021 | 9405 | 0.110 |
Why?
| Antifungal Agents | 2 | 2008 | 339 | 0.110 |
Why?
| Smoking | 1 | 2017 | 512 | 0.110 |
Why?
| Double-Blind Method | 4 | 2017 | 688 | 0.110 |
Why?
| Drug Contamination | 1 | 2012 | 4 | 0.110 |
Why?
| Nebulizers and Vaporizers | 1 | 2013 | 52 | 0.110 |
Why?
| Biophysical Phenomena | 1 | 2012 | 19 | 0.110 |
Why?
| Bacillus | 1 | 2012 | 6 | 0.110 |
Why?
| Binding Sites | 2 | 2014 | 375 | 0.110 |
Why?
| Kangaroo-Mother Care Method | 1 | 2013 | 7 | 0.110 |
Why?
| Albuterol | 1 | 2013 | 54 | 0.110 |
Why?
| Child, Preschool | 4 | 2024 | 3883 | 0.110 |
Why?
| Saliva | 1 | 2013 | 55 | 0.110 |
Why?
| Bronchodilator Agents | 1 | 2013 | 73 | 0.110 |
Why?
| Registries | 1 | 2015 | 522 | 0.110 |
Why?
| Models, Biological | 3 | 2019 | 723 | 0.110 |
Why?
| Cardiotonic Agents | 1 | 2013 | 82 | 0.110 |
Why?
| Drug Overdose | 1 | 2014 | 163 | 0.100 |
Why?
| Hydrocortisone | 1 | 2013 | 107 | 0.100 |
Why?
| Primary Health Care | 3 | 2013 | 360 | 0.100 |
Why?
| Coculture Techniques | 1 | 2012 | 146 | 0.100 |
Why?
| Hypotension | 1 | 2013 | 63 | 0.100 |
Why?
| Dopamine | 1 | 2013 | 172 | 0.100 |
Why?
| DNA, Viral | 1 | 2012 | 134 | 0.100 |
Why?
| Anthropometry | 2 | 2024 | 92 | 0.100 |
Why?
| Calcium Channels, N-Type | 1 | 2011 | 2 | 0.100 |
Why?
| Intralaminar Thalamic Nuclei | 1 | 2011 | 6 | 0.100 |
Why?
| Sequence Analysis, DNA | 1 | 2012 | 238 | 0.100 |
Why?
| Functional Laterality | 1 | 2012 | 89 | 0.100 |
Why?
| Fetal Death | 1 | 2011 | 23 | 0.100 |
Why?
| Dose-Response Relationship, Drug | 4 | 2019 | 1378 | 0.100 |
Why?
| Pain Management | 1 | 2013 | 162 | 0.100 |
Why?
| Polymerase Chain Reaction | 1 | 2012 | 454 | 0.100 |
Why?
| Stem Cell Transplantation | 1 | 2012 | 182 | 0.100 |
Why?
| Patch-Clamp Techniques | 4 | 2012 | 124 | 0.100 |
Why?
| Sleep, REM | 1 | 2011 | 44 | 0.100 |
Why?
| Cells, Cultured | 2 | 2012 | 1581 | 0.100 |
Why?
| Blotting, Western | 1 | 2012 | 601 | 0.100 |
Why?
| Pons | 1 | 2011 | 33 | 0.100 |
Why?
| Brain Waves | 1 | 2011 | 19 | 0.100 |
Why?
| Echoencephalography | 1 | 2011 | 10 | 0.100 |
Why?
| Nerve Fibers | 1 | 2011 | 11 | 0.090 |
Why?
| Neurogenesis | 1 | 2011 | 27 | 0.090 |
Why?
| Stress, Psychological | 1 | 2013 | 261 | 0.090 |
Why?
| Electrocardiography | 1 | 2012 | 262 | 0.090 |
Why?
| Longitudinal Studies | 3 | 2021 | 695 | 0.090 |
Why?
| Central Nervous System Depressants | 1 | 2011 | 79 | 0.090 |
Why?
| Farnesyltranstransferase | 2 | 2007 | 5 | 0.090 |
Why?
| Carbon Dioxide | 1 | 2011 | 94 | 0.090 |
Why?
| Social Environment | 1 | 2011 | 79 | 0.090 |
Why?
| Professional Role | 1 | 2011 | 76 | 0.090 |
Why?
| Atrial Fibrillation | 1 | 2012 | 183 | 0.090 |
Why?
| Administration, Oral | 4 | 2018 | 434 | 0.090 |
Why?
| Cerebellum | 1 | 2011 | 135 | 0.090 |
Why?
| Synapses | 1 | 2010 | 86 | 0.090 |
Why?
| Linear Models | 3 | 2016 | 278 | 0.090 |
Why?
| Parents | 1 | 2013 | 315 | 0.090 |
Why?
| Data Collection | 1 | 2011 | 277 | 0.090 |
Why?
| Teaching | 1 | 2011 | 114 | 0.080 |
Why?
| Cross-Sectional Studies | 3 | 2021 | 1554 | 0.080 |
Why?
| Chronic Disease | 1 | 2012 | 571 | 0.080 |
Why?
| Dihydropyridines | 1 | 2009 | 8 | 0.080 |
Why?
| Health Care Costs | 1 | 2010 | 170 | 0.080 |
Why?
| Drug Design | 1 | 2010 | 121 | 0.080 |
Why?
| Learning | 1 | 2011 | 159 | 0.080 |
Why?
| Gestational Age | 3 | 2019 | 418 | 0.080 |
Why?
| Young Adult | 5 | 2017 | 3981 | 0.080 |
Why?
| Phosphotransferases | 1 | 2008 | 16 | 0.080 |
Why?
| Cooperative Behavior | 1 | 2010 | 227 | 0.080 |
Why?
| Body Weight | 2 | 2021 | 512 | 0.080 |
Why?
| Diet, High-Fat | 2 | 2021 | 220 | 0.080 |
Why?
| Magnetic Resonance Imaging | 3 | 2021 | 1541 | 0.080 |
Why?
| Liver | 3 | 2019 | 1116 | 0.080 |
Why?
| Electroencephalography | 1 | 2010 | 307 | 0.080 |
Why?
| Mice, Inbred Strains | 2 | 2019 | 161 | 0.080 |
Why?
| Urea | 1 | 2008 | 77 | 0.080 |
Why?
| Stomach Neoplasms | 2 | 2008 | 179 | 0.080 |
Why?
| Beverages | 2 | 2008 | 56 | 0.080 |
Why?
| Triazines | 1 | 2008 | 24 | 0.080 |
Why?
| Logistic Models | 2 | 2012 | 889 | 0.080 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2008 | 51 | 0.080 |
Why?
| Adolescent | 5 | 2021 | 6390 | 0.080 |
Why?
| Breast Neoplasms | 1 | 2017 | 1179 | 0.080 |
Why?
| Plasmodium falciparum | 1 | 2007 | 18 | 0.070 |
Why?
| Antimalarials | 1 | 2007 | 23 | 0.070 |
Why?
| Swimming | 1 | 2006 | 21 | 0.070 |
Why?
| Bicycling | 1 | 2006 | 25 | 0.070 |
Why?
| Running | 1 | 2006 | 17 | 0.070 |
Why?
| Glioma | 1 | 2007 | 79 | 0.070 |
Why?
| Monitoring, Physiologic | 2 | 2019 | 120 | 0.070 |
Why?
| Chromatography, High Pressure Liquid | 2 | 2018 | 327 | 0.070 |
Why?
| Central Nervous System Stimulants | 1 | 2009 | 213 | 0.070 |
Why?
| Motor Activity | 3 | 2014 | 229 | 0.070 |
Why?
| Proportional Hazards Models | 1 | 2007 | 410 | 0.070 |
Why?
| Sulfonamides | 1 | 2007 | 128 | 0.070 |
Why?
| Fetus | 3 | 2014 | 216 | 0.070 |
Why?
| Receptors, Vasopressin | 1 | 2005 | 23 | 0.070 |
Why?
| Prospective Studies | 3 | 2019 | 2379 | 0.070 |
Why?
| Ambulatory Care | 2 | 2021 | 222 | 0.060 |
Why?
| Dogs | 2 | 2020 | 185 | 0.060 |
Why?
| Multiple Myeloma | 2 | 2012 | 2954 | 0.060 |
Why?
| Cell Survival | 3 | 2017 | 602 | 0.060 |
Why?
| Alkyl and Aryl Transferases | 1 | 2005 | 5 | 0.060 |
Why?
| Poliomyelitis | 1 | 2005 | 5 | 0.060 |
Why?
| Mice, Inbred C57BL | 2 | 2021 | 1819 | 0.060 |
Why?
| Benzodiazepines | 1 | 2005 | 73 | 0.060 |
Why?
| Spheroids, Cellular | 1 | 2005 | 25 | 0.060 |
Why?
| Ambulatory Care Facilities | 2 | 2021 | 125 | 0.060 |
Why?
| Area Under Curve | 3 | 2014 | 178 | 0.060 |
Why?
| Kinetics | 2 | 2020 | 631 | 0.060 |
Why?
| Cyclin-Dependent Kinases | 1 | 2004 | 28 | 0.060 |
Why?
| beta-Cyclodextrins | 1 | 2004 | 16 | 0.060 |
Why?
| Predictive Value of Tests | 2 | 2017 | 905 | 0.060 |
Why?
| Thiazoles | 1 | 2004 | 53 | 0.060 |
Why?
| Brain Neoplasms | 1 | 2007 | 288 | 0.060 |
Why?
| Protein Binding | 3 | 2014 | 665 | 0.060 |
Why?
| Placebos | 2 | 2014 | 86 | 0.060 |
Why?
| Louisiana | 2 | 2019 | 39 | 0.050 |
Why?
| Insurance, Psychiatric | 1 | 2003 | 3 | 0.050 |
Why?
| Insurance Benefits | 1 | 2003 | 7 | 0.050 |
Why?
| Cell Proliferation | 4 | 2008 | 1013 | 0.050 |
Why?
| Odds Ratio | 2 | 2016 | 546 | 0.050 |
Why?
| Health Services | 1 | 2003 | 67 | 0.050 |
Why?
| Community Mental Health Services | 1 | 2003 | 45 | 0.050 |
Why?
| Palmitates | 1 | 2022 | 29 | 0.050 |
Why?
| Drug Evaluation, Preclinical | 2 | 2017 | 143 | 0.050 |
Why?
| L-Lactate Dehydrogenase | 1 | 2022 | 66 | 0.050 |
Why?
| Models, Molecular | 3 | 2009 | 341 | 0.050 |
Why?
| Sex Factors | 2 | 2019 | 697 | 0.050 |
Why?
| Clinical Competence | 2 | 2018 | 392 | 0.050 |
Why?
| Reproducibility of Results | 2 | 2019 | 1185 | 0.050 |
Why?
| Statistics, Nonparametric | 2 | 2012 | 193 | 0.050 |
Why?
| Physical Therapy Modalities | 1 | 2021 | 36 | 0.050 |
Why?
| Medically Uninsured | 1 | 2021 | 44 | 0.050 |
Why?
| Glucose Tolerance Test | 1 | 2021 | 56 | 0.050 |
Why?
| Carbachol | 2 | 2011 | 27 | 0.050 |
Why?
| Psychiatric Status Rating Scales | 2 | 2013 | 319 | 0.050 |
Why?
| Postural Balance | 1 | 2021 | 56 | 0.050 |
Why?
| Sodium Channel Blockers | 2 | 2011 | 13 | 0.050 |
Why?
| Athletes | 1 | 2021 | 102 | 0.050 |
Why?
| Membrane Potentials | 2 | 2011 | 117 | 0.050 |
Why?
| Weight Gain | 1 | 2022 | 239 | 0.050 |
Why?
| Diet, Fat-Restricted | 1 | 2020 | 11 | 0.050 |
Why?
| Analysis of Variance | 2 | 2013 | 564 | 0.050 |
Why?
| Veterans Health | 1 | 2021 | 62 | 0.050 |
Why?
| Attitude | 1 | 2021 | 69 | 0.050 |
Why?
| Mice, Obese | 1 | 2020 | 21 | 0.050 |
Why?
| Fatty Acids | 1 | 2021 | 145 | 0.050 |
Why?
| Body Fat Distribution | 1 | 2020 | 9 | 0.050 |
Why?
| Cytopathogenic Effect, Viral | 1 | 2020 | 5 | 0.050 |
Why?
| Macaca | 1 | 2020 | 7 | 0.050 |
Why?
| Animals, Newborn | 2 | 2012 | 368 | 0.040 |
Why?
| Reaction Time | 1 | 2021 | 216 | 0.040 |
Why?
| Adipose Tissue, Brown | 1 | 2020 | 40 | 0.040 |
Why?
| Lipid Metabolism | 1 | 2021 | 175 | 0.040 |
Why?
| Absorptiometry, Photon | 1 | 2020 | 153 | 0.040 |
Why?
| Oxidation-Reduction | 1 | 2021 | 320 | 0.040 |
Why?
| Alcoholism | 1 | 2003 | 233 | 0.040 |
Why?
| Neuroimaging | 1 | 2020 | 85 | 0.040 |
Why?
| Memory | 1 | 2020 | 117 | 0.040 |
Why?
| Sex Characteristics | 1 | 2021 | 191 | 0.040 |
Why?
| Exercise | 1 | 2024 | 503 | 0.040 |
Why?
| Patient Compliance | 2 | 2014 | 230 | 0.040 |
Why?
| Family Relations | 1 | 2019 | 22 | 0.040 |
Why?
| Cohort Studies | 2 | 2016 | 1422 | 0.040 |
Why?
| Language | 1 | 2020 | 134 | 0.040 |
Why?
| Phylogeny | 1 | 2020 | 234 | 0.040 |
Why?
| Proteomics | 1 | 2022 | 330 | 0.040 |
Why?
| Drug Synergism | 1 | 2019 | 151 | 0.040 |
Why?
| Students | 1 | 2021 | 211 | 0.040 |
Why?
| Mothers | 1 | 2021 | 254 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 170 | 0.040 |
Why?
| Specialty Boards | 1 | 2018 | 24 | 0.040 |
Why?
| Interpersonal Relations | 1 | 2019 | 105 | 0.040 |
Why?
| Retrospective Studies | 2 | 2012 | 6134 | 0.040 |
Why?
| Neuropsychological Tests | 1 | 2020 | 355 | 0.040 |
Why?
| Mice, Knockout | 1 | 2021 | 846 | 0.040 |
Why?
| Caco-2 Cells | 2 | 2008 | 26 | 0.040 |
Why?
| Animals, Outbred Strains | 1 | 2017 | 11 | 0.040 |
Why?
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2017 | 9 | 0.040 |
Why?
| Social Support | 1 | 2019 | 264 | 0.040 |
Why?
| Transglutaminases | 1 | 2017 | 15 | 0.040 |
Why?
| Parietal Lobe | 1 | 2017 | 26 | 0.040 |
Why?
| Toxicity Tests | 1 | 2017 | 54 | 0.040 |
Why?
| Adaptation, Psychological | 1 | 2019 | 223 | 0.040 |
Why?
| Cell Line | 1 | 2020 | 1021 | 0.040 |
Why?
| Mice, Inbred BALB C | 2 | 2008 | 305 | 0.040 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 63 | 0.040 |
Why?
| Plant Extracts | 1 | 2019 | 171 | 0.040 |
Why?
| Platelet Aggregation | 1 | 2017 | 71 | 0.040 |
Why?
| Emergency Service, Hospital | 1 | 2021 | 484 | 0.040 |
Why?
| Organ Size | 1 | 2017 | 225 | 0.040 |
Why?
| Polysaccharides | 1 | 2017 | 51 | 0.040 |
Why?
| Feeding Behavior | 1 | 2018 | 177 | 0.040 |
Why?
| Prognosis | 1 | 2022 | 1954 | 0.040 |
Why?
| Accidental Falls | 1 | 2018 | 97 | 0.040 |
Why?
| Educational Measurement | 1 | 2018 | 207 | 0.040 |
Why?
| Education, Medical, Graduate | 1 | 2019 | 205 | 0.040 |
Why?
| Medicine | 1 | 2017 | 56 | 0.030 |
Why?
| Prefrontal Cortex | 1 | 2017 | 83 | 0.030 |
Why?
| Mice, Nude | 2 | 2009 | 254 | 0.030 |
Why?
| Psychomotor Performance | 1 | 2017 | 130 | 0.030 |
Why?
| Protein Transport | 1 | 2017 | 183 | 0.030 |
Why?
| Adrenergic beta-Antagonists | 1 | 2017 | 105 | 0.030 |
Why?
| Inhibitory Concentration 50 | 2 | 2008 | 75 | 0.030 |
Why?
| Cannabis | 1 | 2019 | 145 | 0.030 |
Why?
| Umbilical Arteries | 1 | 2016 | 22 | 0.030 |
Why?
| Pharmaceutical Solutions | 2 | 2008 | 8 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2017 | 236 | 0.030 |
Why?
| Autonomic Nervous System | 1 | 2016 | 57 | 0.030 |
Why?
| Ultrasonography, Doppler, Transcranial | 1 | 2016 | 25 | 0.030 |
Why?
| Apgar Score | 1 | 2016 | 35 | 0.030 |
Why?
| Molecular Structure | 2 | 2008 | 296 | 0.030 |
Why?
| Tandem Mass Spectrometry | 1 | 2017 | 231 | 0.030 |
Why?
| Prevalence | 1 | 2019 | 951 | 0.030 |
Why?
| Echocardiography | 1 | 2018 | 375 | 0.030 |
Why?
| Infant, Extremely Premature | 1 | 2016 | 35 | 0.030 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2017 | 174 | 0.030 |
Why?
| Up-Regulation | 1 | 2017 | 453 | 0.030 |
Why?
| Calcium | 1 | 2017 | 400 | 0.030 |
Why?
| Cost of Illness | 1 | 2015 | 117 | 0.030 |
Why?
| Binding Sites, Antibody | 1 | 2014 | 16 | 0.030 |
Why?
| GABA Agonists | 1 | 2014 | 15 | 0.030 |
Why?
| Diagnosis, Dual (Psychiatry) | 1 | 2014 | 41 | 0.030 |
Why?
| Half-Life | 1 | 2014 | 87 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2016 | 581 | 0.030 |
Why?
| Locomotion | 1 | 2014 | 92 | 0.030 |
Why?
| Gene Expression Profiling | 1 | 2018 | 1037 | 0.030 |
Why?
| CD4 Lymphocyte Count | 1 | 2013 | 32 | 0.030 |
Why?
| MicroRNAs | 1 | 2017 | 355 | 0.030 |
Why?
| Particle Size | 1 | 2013 | 80 | 0.030 |
Why?
| Amphetamine-Related Disorders | 1 | 2014 | 94 | 0.030 |
Why?
| Administration, Inhalation | 1 | 2013 | 108 | 0.030 |
Why?
| T-Lymphocyte Subsets | 1 | 2013 | 39 | 0.030 |
Why?
| Aerosols | 1 | 2013 | 73 | 0.030 |
Why?
| Plasma | 1 | 2013 | 42 | 0.030 |
Why?
| Biophysics | 1 | 2012 | 16 | 0.030 |
Why?
| Infant, Extremely Low Birth Weight | 1 | 2013 | 27 | 0.030 |
Why?
| Viral Load | 1 | 2013 | 77 | 0.030 |
Why?
| Nasal Cavity | 1 | 2013 | 9 | 0.030 |
Why?
| Touch | 1 | 2013 | 25 | 0.030 |
Why?
| Theophylline | 1 | 2012 | 21 | 0.030 |
Why?
| Ion Channel Gating | 1 | 2012 | 39 | 0.030 |
Why?
| Infant Behavior | 1 | 2013 | 18 | 0.030 |
Why?
| Medically Underserved Area | 1 | 2013 | 42 | 0.030 |
Why?
| Neurotransmitter Agents | 1 | 2012 | 35 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2014 | 381 | 0.030 |
Why?
| Electric Stimulation | 1 | 2012 | 118 | 0.030 |
Why?
| Remission Induction | 1 | 2013 | 207 | 0.030 |
Why?
| Equipment Design | 1 | 2013 | 285 | 0.030 |
Why?
| Medication Adherence | 1 | 2014 | 130 | 0.030 |
Why?
| Intensive Care Units, Neonatal | 1 | 2014 | 115 | 0.030 |
Why?
| Sleep | 1 | 2014 | 184 | 0.030 |
Why?
| Heart Atria | 1 | 2012 | 56 | 0.030 |
Why?
| Systole | 1 | 2012 | 71 | 0.030 |
Why?
| Caffeine | 1 | 2012 | 66 | 0.030 |
Why?
| Psychotherapy | 1 | 2013 | 106 | 0.030 |
Why?
| Ion Channels | 1 | 2012 | 76 | 0.030 |
Why?
| Recurrence | 1 | 2014 | 662 | 0.030 |
Why?
| Infant | 1 | 2020 | 3563 | 0.030 |
Why?
| omega-Agatoxin IVA | 1 | 2011 | 1 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2014 | 636 | 0.030 |
Why?
| Antidepressive Agents | 1 | 2013 | 176 | 0.020 |
Why?
| Ventricular Dysfunction, Left | 1 | 2012 | 94 | 0.020 |
Why?
| Oscillometry | 1 | 2011 | 8 | 0.020 |
Why?
| Survival Analysis | 1 | 2013 | 666 | 0.020 |
Why?
| Sodium Channels | 1 | 2011 | 14 | 0.020 |
Why?
| Calcium Channel Blockers | 1 | 2011 | 63 | 0.020 |
Why?
| Secondary Prevention | 1 | 2011 | 78 | 0.020 |
Why?
| Cystic Fibrosis | 1 | 2013 | 149 | 0.020 |
Why?
| Acculturation | 1 | 2011 | 21 | 0.020 |
Why?
| Principal Component Analysis | 1 | 2011 | 55 | 0.020 |
Why?
| Social Identification | 1 | 2011 | 21 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2011 | 113 | 0.020 |
Why?
| Femoral Artery | 1 | 2011 | 102 | 0.020 |
Why?
| Microscopy, Confocal | 1 | 2011 | 89 | 0.020 |
Why?
| Clinical Clerkship | 1 | 2011 | 30 | 0.020 |
Why?
| Statistics as Topic | 1 | 2011 | 87 | 0.020 |
Why?
| Vesicular Glutamate Transport Protein 2 | 1 | 2010 | 6 | 0.020 |
Why?
| Transplantation, Autologous | 1 | 2012 | 469 | 0.020 |
Why?
| Cerebellar Cortex | 1 | 2010 | 6 | 0.020 |
Why?
| Ultrasonography | 1 | 2012 | 437 | 0.020 |
Why?
| Tetrodotoxin | 1 | 2010 | 10 | 0.020 |
Why?
| Muscarinic Agonists | 1 | 2010 | 10 | 0.020 |
Why?
| Electrophysiological Phenomena | 1 | 2010 | 18 | 0.020 |
Why?
| N-Methylaspartate | 1 | 2010 | 27 | 0.020 |
Why?
| Theta Rhythm | 1 | 2010 | 10 | 0.020 |
Why?
| Potassium Channel Blockers | 1 | 2010 | 16 | 0.020 |
Why?
| Kainic Acid | 1 | 2010 | 29 | 0.020 |
Why?
| Schools, Medical | 1 | 2011 | 70 | 0.020 |
Why?
| Disease Progression | 1 | 2013 | 831 | 0.020 |
Why?
| Potassium Channels | 1 | 2010 | 32 | 0.020 |
Why?
| Kidney Diseases | 1 | 2012 | 214 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2011 | 465 | 0.020 |
Why?
| Cell Count | 1 | 2010 | 149 | 0.020 |
Why?
| Pregnancy Outcome | 1 | 2011 | 237 | 0.020 |
Why?
| Stereotyped Behavior | 1 | 2009 | 17 | 0.020 |
Why?
| Age Factors | 1 | 2013 | 1092 | 0.020 |
Why?
| Image Processing, Computer-Assisted | 1 | 2011 | 246 | 0.020 |
Why?
| Dextroamphetamine | 1 | 2009 | 39 | 0.020 |
Why?
| Incidence | 1 | 2012 | 1006 | 0.020 |
Why?
| Blood Proteins | 1 | 2009 | 82 | 0.020 |
Why?
| Fetal Development | 1 | 2009 | 59 | 0.020 |
Why?
| Solubility | 1 | 2009 | 71 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2009 | 213 | 0.020 |
Why?
| fms-Like Tyrosine Kinase 3 | 1 | 2008 | 16 | 0.020 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 32 | 0.020 |
Why?
| Ether-A-Go-Go Potassium Channels | 1 | 2008 | 5 | 0.020 |
Why?
| Kidney | 1 | 2012 | 672 | 0.020 |
Why?
| Risk Assessment | 1 | 2012 | 1262 | 0.020 |
Why?
| Parasitic Sensitivity Tests | 1 | 2007 | 2 | 0.020 |
Why?
| Dealkylation | 1 | 2007 | 4 | 0.020 |
Why?
| Plasmodium berghei | 1 | 2007 | 4 | 0.020 |
Why?
| Cell Membrane Permeability | 1 | 2007 | 28 | 0.020 |
Why?
| Mutagenicity Tests | 1 | 2007 | 41 | 0.020 |
Why?
| Protein Conformation | 1 | 2008 | 168 | 0.020 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2008 | 78 | 0.020 |
Why?
| Hypertension | 1 | 2012 | 537 | 0.020 |
Why?
| Glutathione Transferase | 1 | 2008 | 174 | 0.020 |
Why?
| Bile Ducts | 1 | 2007 | 45 | 0.020 |
Why?
| Malaria | 1 | 2007 | 37 | 0.020 |
Why?
| Physical Endurance | 1 | 2006 | 30 | 0.020 |
Why?
| Exercise Tolerance | 1 | 2006 | 41 | 0.020 |
Why?
| Hepatocytes | 1 | 2008 | 182 | 0.020 |
Why?
| Computer Simulation | 1 | 2007 | 280 | 0.020 |
Why?
| Respiration | 1 | 2006 | 99 | 0.020 |
Why?
| Molecular Weight | 1 | 2005 | 85 | 0.020 |
Why?
| Benzazepines | 1 | 2005 | 20 | 0.020 |
Why?
| Oxygen Consumption | 1 | 2006 | 188 | 0.020 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2006 | 245 | 0.020 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2007 | 550 | 0.020 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2005 | 140 | 0.020 |
Why?
| Cyclodextrins | 1 | 2004 | 18 | 0.010 |
Why?
| Tumor Cells, Cultured | 1 | 2005 | 468 | 0.010 |
Why?
| Biological Availability | 1 | 2004 | 96 | 0.010 |
Why?
| Leukemia | 1 | 2004 | 65 | 0.010 |
Why?
| Neoplasms, Experimental | 1 | 2004 | 114 | 0.010 |
Why?
| Gatekeeping | 1 | 2003 | 9 | 0.010 |
Why?
| Cost Control | 1 | 2003 | 13 | 0.010 |
Why?
| Tennessee | 1 | 2003 | 37 | 0.010 |
Why?
| Cost Sharing | 1 | 2003 | 16 | 0.010 |
Why?
| Georgia | 1 | 2003 | 41 | 0.010 |
Why?
| Alabama | 1 | 2003 | 67 | 0.010 |
Why?
| Mississippi | 1 | 2003 | 88 | 0.010 |
Why?
| Health Policy | 1 | 2003 | 154 | 0.010 |
Why?
|
|
Williams's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|